dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Blood coagulation components (type: enzyme)
Target: coagulation factor XI

Ligand: osocimab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.619999885559082 pKd
Reference (Journal): Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI.
Published in: J Mol Biol

Ligand: milvexian (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.960000038146973 pKi
Reference (Journal): Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.
Published in: J Med Chem

Ligand: FXIa inhibitor 3f (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.770000457763672 pKi
Reference (Journal): Discovery of Potent and Orally Bioavailable Pyridine N-Oxide-Based Factor XIa Inhibitors through Exploiting Nonclassical Interactions.
Published in: J Med Chem

Ligand: EP-7041 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report.
Published in: Crit Care Explor

Ligand: alpha-ketothiazole analogue 36 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.5 pIC50
Reference (Journal): Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
Published in: Bioorg Med Chem

Ligand: abelacimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 11.329999923706055 pKd
Reference (Journal): MAA868 locks factor XIa in a zymogen-like state.
Published in: Blood

Ligand: abelacimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 11.890000343322754 pKd
Reference (Journal): MAA868 locks factor XIa in a zymogen-like state.
Published in: Blood
Target family: Blood coagulation components (type: enzyme)
Target: coagulation factor VIII

Ligand: drotrecogin alfa (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2001), EMA (2009)
Primary target: yes
Median affinity:  -
Reference (Journal): Recombinant human activated protein C for severe sepsis.
Published in: N Engl J Med

Ligand: drotrecogin alfa (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2001), EMA (2009)
Primary target: yes
Median affinity:  -
Reference (Journal): Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.
Published in: Pharmacotherapy
Target family: Blood coagulation components (type: enzyme)
Target: coagulation factor V

Ligand: drotrecogin alfa (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2001), EMA (2009)
Primary target: yes
Median affinity:  -
Reference (Journal): Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.
Published in: Pharmacotherapy

Ligand: drotrecogin alfa (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2001), EMA (2009)
Primary target: yes
Median affinity:  -
Reference (Journal): Recombinant human activated protein C for severe sepsis.
Published in: N Engl J Med
Target family: Blood coagulation components (type: enzyme)
Target: serpin family C member 1

Ligand: tinzaparin (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2000)
Primary target: yes
Median affinity:  -
Reference (Journal): Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.
Published in: Drugs
Target family: Blood coagulation components (type: enzyme)
Target: coagulation factor III, tissue factor

Ligand: tisotumab vedotin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2021)
Primary target: yes
Median affinity:  -
Reference (Journal): An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Published in: Cancer Res
Target family: Blood coagulation components (type: enzyme)
Target: serpin family C member 1

Ligand: heparin (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (1939)
Primary target: yes
Median affinity: 7.849999904632568 pKd
Reference (Journal): Affinity capillary electrophoresis in binding study of antithrombin to heparin from different sources.
Published in: Talanta

Ligand: fondaparinux (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2001), EMA (2002)
Primary target: yes
Median affinity: 7.489999771118164 pKd
Reference (Journal): Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins.
Published in: Clin Pharmacokinet

Ligand: enoxaparin (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (1993), FDA (2016)
Primary target: yes
Median affinity:  -
Reference (Journal): A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
Published in: Thromb Haemost

Ligand: danaparoid (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (1996), still marketed outside the U.S.
Primary target: yes
Median affinity:  -
Reference (Journal): Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
Published in: Clin Pharm

Ligand: danaparoid (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (1996), still marketed outside the U.S.
Primary target: yes
Median affinity:  -
Reference (Journal): Heparin versus danaproid for prevention of venous thromboembolism after hip surgery.
Published in: J Orthop Surg (Hong Kong)
Target family: Bradykinin receptors (type: gpcr)
Target: B<sub>2</sub> receptor

Ligand: bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657.
Published in: Mol Pharmacol
Target family: Bromodomain kinase (BRDK) family (type: enzyme)
Target: bromodomain containing 2

Ligand: WNY0824 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.389999866485596 pIC50
Reference (Journal): Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Published in: Eur J Med Chem
Target family: Bromodomain kinase (BRDK) family (type: enzyme)
Target: bromodomain containing 9

Ligand: TP-472 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.480000019073486 pIC50
Reference (Webpage): TP-472 A BRD9/7 Probe

Ligand: LP99 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7 pKd
Reference (Journal): LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor.
Published in: Angew Chem Int Ed Engl

Ligand: I-BRD9 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
Published in: J Med Chem

Ligand: dBRD9-A (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.079999923706055 pIC50
Reference (Journal): Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Published in: Elife

Ligand: dBRD9 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.980000019073486 pIC50
Reference (Journal): Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.
Published in: Angew Chem Int Ed Engl

Ligand: compound 50 [PMID: 24313754] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.5 pIC50
Reference (Journal): [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
Published in: J Med Chem

Ligand: BI-9564 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pKd
Reference (Webpage): BI-9564 A chemical probe for BRD9 and BRD7

Ligand: BI-7273 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Published in: J Med Chem
Target family: Bromodomain kinase (BRDK) family (type: enzyme)
Target: bromodomain containing 7

Ligand: TP-472 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.46999979019165 pIC50
Reference (Webpage): TP-472 A BRD9/7 Probe

Ligand: LP99 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6 pKd
Reference (Journal): LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor.
Published in: Angew Chem Int Ed Engl

Ligand: BI-9564 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.619999885559082 pKd
Reference (Webpage): BI-9564 A chemical probe for BRD9 and BRD7
Target family: Bromodomain kinase (BRDK) family (type: enzyme)
Target: bromodomain containing 1

Ligand: NI-57 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.96999979019165 pKd
Reference (Webpage): NI-57 – a chemical probe for BRPF bromodomains.

Ligand: BAY-299 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.220000267028809 pIC50
Reference (Webpage): BAY-299 A probe for BRD1 and TAF1
Target family: BRSK subfamily (type: enzyme)
Target: BR serine/threonine kinase 1

Ligand: CCT244747 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
Published in: J Med Chem
Target family: BRSK subfamily (type: enzyme)
Target: BR serine/threonine kinase 2

Ligand: CCT244747 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
Published in: J Med Chem

Ligand: SU6656 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): The selectivity of protein kinase inhibitors: a further update.
Published in: Biochem J
Target family: BTB (POZ) domain containing TFs (type: other_protein)
Target: BCL6 transcription repressor

Ligand: JNJ-65234637 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pKd
Reference (Journal): Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.
Published in: ACS Med Chem Lett

Ligand: FX1 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 5.150000095367432 pKd
Reference (Journal): Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Published in: J Clin Invest

Ligand: BI-3802 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
Published in: Cell Rep

Ligand: compound 8c [PMID: 28760529] (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.
Published in: Bioorg Med Chem

Ligand: BCL6 PROTAC 15 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.920000076293945 pIC50
Reference (Journal): Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
Published in: ACS Chem Biol

Ligand: compound 8c [PMID: 28760529] (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.139999866485596 pIC50
Reference (Journal): Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.
Published in: Bioorg Med Chem
Target family: Bub family (type: enzyme)
Target: BUB1 mitotic checkpoint serine/threonine kinase

Ligand: BAY-320 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.170000076293945 pIC50
Reference (Journal): Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524.
Published in: Elife

Ligand: BAY-524 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.349999904632568 pIC50
Reference (Journal): Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524.
Published in: Elife

Ligand: compound 2-1-1 [PMID: 24900824] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Novel cycloalkenepyrazoles as inhibitors of bub1 kinase.
Published in: ACS Med Chem Lett

Ligand: compound 2-13-1 [PMID: 24900824] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Novel cycloalkenepyrazoles as inhibitors of bub1 kinase.
Published in: ACS Med Chem Lett

Ligand: compound 2-3-1 [PMID: 24900824] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Novel cycloalkenepyrazoles as inhibitors of bub1 kinase.
Published in: ACS Med Chem Lett

Ligand: compound 2-3-2 [PMID: 24900824] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Novel cycloalkenepyrazoles as inhibitors of bub1 kinase.
Published in: ACS Med Chem Lett
Target family: Butyrophilin and butyrophilin-like proteins (type: other_protein)
Target: butyrophilin subfamily 3 member A1

Ligand: POM2-C-HMBP (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors.
Published in: J Immunol
Target family: C12: Ubiquitin C-terminal hydrolase (type: enzyme)
Target: ubiquitin C-terminal hydrolase L1

Ligand: LDN-91946 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.639999866485596 pKi
Reference (Journal): Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors.
Published in: Bioorg Med Chem Lett
Target family: C12: Ubiquitin C-terminal hydrolase (type: enzyme)
Target: ubiquitin C-terminal hydrolase L3

Ligand: compound 6 [PMID: 17948018] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.21999979019165 pIC50
Reference (Journal): Mechanisms, biology and inhibitors of deubiquitinating enzymes.
Published in: Nat Chem Biol
Target family: C13: Legumain (type: enzyme)
Target: legumain

Ligand: compound 18 [PMID: 38090813] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.109999656677246 pIC50
Reference (Journal): Discovery of Orally Available and Brain Penetrant AEP Inhibitors.
Published in: J Med Chem

Ligand: compound 7u [PMID: 24775305] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.050000190734863 pIC50
Reference (Journal): P3 SAR exploration of biphenyl carbamate based Legumain inhibitors.
Published in: Bioorg Med Chem Lett
Target family: C14: Caspase (type: enzyme)
Target: Caspase 1

Ligand: AS101 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme.
Published in: J Interferon Cytokine Res

Ligand: M826 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: pralnacasan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pKi
Reference (Journal): Caspase inhibitors: a pharmaceutical industry perspective.
Published in: Curr Top Med Chem

Ligand: uracil 20 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.010000228881836 pIC50
Reference (Journal): Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.
Published in: J Med Chem

Ligand: VRT-043198 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.100000381469727 pKi
Reference (Journal): (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18.
Published in: J Pharmacol Exp Ther

Ligand: Z-YVAD-FMK (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines.
Published in: J Nutr
Target family: C14: Caspase (type: enzyme)
Target: Caspase 14

Ligand: grassystatin A (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.300000190734863 pIC50
Reference (Journal): Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
Published in: J Med Chem
Target family: C14: Caspase (type: enzyme)
Target: Caspase 2

Ligand: compound 4 [PMID: 12408711] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.019999980926514 pKi
Reference (Journal): Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.
Published in: J Med Chem

Ligand: Z-VDVAD-FMK (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells.
Published in: Exp Cell Res
Target family: C14: Caspase (type: enzyme)
Target: Caspase 3

Ligand: Ac-DEVD-CHO (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.8 pIC50
Reference (Journal): Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study.
Published in: Eur J Med Chem

Ligand: AZ10417808 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.610000133514404 pKi
Reference (Journal): Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis.
Published in: J Pharmacol Exp Ther

Ligand: compound 4 [PMID: 12408711] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.300000190734863 pKi
Reference (Journal): Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.
Published in: J Med Chem

Ligand: M826 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.300000190734863 pKi
Reference (Journal): Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: PAC1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.
Published in: Nat Chem Biol

Ligand: PETCM (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway.
Published in: Science

Ligand: Z-DEVD-FMK (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3.
Published in: J Biol Chem

Ligand: Z-DQMD-FMK (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells.
Published in: Mod Pathol